|
|
|
|
FASgen signs research and licensing agreement with Centocor
This agreement will give Centocor and its Ortho Biotech Oncology R&D division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of...
|
|
|
FASgen signs research and licensing agreement with Centocor
FASgen, a drug development company, has entered into a research and licensing agreement with Centocor, a biopharmaceutical company.The economic terms of the research collaboration were not disclosed. This agreement will give Centocor...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
BALTIMORE, Jan.6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research...
|
|
|
Examine the World Biotechnology Reagents Market
/World-Biotechnology-Reagents--Market.html This report analyzes the worldwide markets for Biotechnology Reagents in Millions of US$.The specific product segments analyzed are Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
PRNewswire/ -- FASgen, Inc.is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
BALTIMORE, Jan.6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. (JNJ)
BALTIMORE, Jan.6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
PRNewswire/ -- FASgen, Inc.is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development...
|
|
|
Examine the World Biotechnology Reagents Market
NEW YORK--(BUSINESS WIRE)-- Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.http://www.reportlinker.com/p098414/World-Biotechnology-Reagents-...
|
|
|
Examine the World Biotechnology Reagents Market
(BUSINESS WIRE) -- Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.World Biotechnology Reagents Market http://www.reportlinker.com/p098414...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
FASgen, Inc.is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
BALTIMORE, Jan.6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research...
|
|
|
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc
BALTIMORE, Jan.6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research...
|
|
|
PriCara Recalls 50 mcg/hr DURAGESIC (fentanyl transdermal system) CII Pain Patches
PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said that one lot of 50 microgram/hour (mcg/hr) DURAGESIC (fentanyl transdermal system) CII patches sold by PriCara in the United States and one lot of 50 mcg/hr fentanyl...
|
|
|
PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches Press Release to Press Releases Press Releases Other Strength Patches (12.5, 25, 75 and 100 mcg/hr) Not Affected RARITAN, N.J., Dec.31 /PRwire/ -- PriCara(R),...
|
|
|
Duragesic Recall Causes More Patch Woes for J&J
Johnson & Johnsons PriCara unit is recalling two lots of its Duragesic fentanyl pain patch, according to the WSJ.The patch is used for opioid-tolerant patients who need round-the-clock pain relief. Fentanyl is also highly...
|
|
|
Biovail recalls certain lots of Ultram ER 100mg tabs
Biovail Corporation announced a voluntary recall of certain lots of Ultram ER (extended-release tramadol hydrochloride) 100mg tablets from pharmacies and wholesalers.Biovail is taking this action as a result of certain lots being out-of...
|
|
|
PriCara recalls 50mcg/hr Duragesic CII pain patches
PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced that one lot of 50mcg/hr Duragesic CII patches sold by PriCara in the US and one lot of 50mcg/hr fentanyl patches sold by Sandoz in the US are being voluntarily...
|
|
|
Pricara recalls 50 mcg/hr Duragesic CII pain patches
PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, stated that one lot of 50 microgram/hour (mcg/hr) Duragesic (fentanyl transdermal system) CII patches sold by PriCara in the United States and one lot of 50 mcg/hr...
|
|
|
PriCara„ Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
RARITAN, N.J., Dec.31 /PRNewswire/ -- PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC (fentanyl transdermal system) CII patches sold by PriCara in the...
|
|
|
Johnson & Johnson's Subsidiary Recalls Pain Patch Duragesic
(RTTNews) - Wednesday, PriCara, a unit of consumer and health care products company Johnson & Johnson (JNJ), said it has voluntarily recalled two lots of the pain patch Duragesic or fentanyl, citing possible tears in the reservoir...
|
|
|
J&J disputes articles on its funding of research
(The Philadelphia Inquirer - McClatchy-Tribune Information Services via COMTEX) -- JNJ | Quote | Chart | News | PowerRating -- A Boston hospital's suspension of industry-funded research by a prominent child psychiatrist prompted Johnson &...
|
|
|
J&J disputes articles on its funding of research
A Boston hospital's suspension of industry-funded research by a prominent child psychiatrist prompted Johnson & Johnson yesterday to say the media had misrepresented its work with the doctor.Ortho-McNeil-Janssen Pharmaceuticals...
|
|
|
Biovail recalls certain lots of Ultram ER 100mg tablets
Biovail said that it is taking this action as a result of certain lots being out-of-specification by approximately 1% with respect to maximum dissolution at the eight-hour mark.This minor dissolution variance does not impact patient...
|
|
|
PriCara Recalls 50 mcg/hr Duragesic (fentanyl transdermal system) CII Pain Patches
/PRNewswire/ -- PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) CII patches sold by PriCara in the United States and...
|
